Skip to content
type1.science

Sinocare iCan i3 / GlucoMen iCan

Sinocare

What it is

A 15-day standalone CGM sold under regional branding. A 2026 pediatric paper reports 8.89% MARD in 75 per-protocol participants; this does not establish superiority over another CGM or US clearance.

Editorial review: . What was checked and what remains uncertain.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews.

Full sources ↓Full discussion ↓Report an issue →

Available nowModerate evidenceOfficial site ↗

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
Benefit or performance
Accuracy: 8.89% MARD in 75 pediatric per-protocol participants; no head-to-head superiority.[2]
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the record-specific review limits for gaps in evidence, source access or availability checks.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Default calculation: 65 × 20 + 45 × 15 + 12 × 15 + 88 × 10 + 90 × 10 + 65 × 10 + 70 × 10 + 0 × 5 + 50 × 5 = 5535; divide by total weight 100. Unrounded weighted result: 55.35.

Accuracy65

8.89% MARD in 75 pediatric per-protocol participants; no head-to-head superiority.[2]

Low lag45

Three-minute updates do not quantify physiological lag.[1]

Interoperability12

Standalone CGM; no commercial AID integration established.[1]

Sensor lifespan88

15-day specification; paper mean wear 14.4 days.[1]

No calibration90

Factory-calibrated platform described in clinical report.[3]

Alerts & prediction65

Configurable alerts; regional instructions apply.[1]

Form factor70

6 g manufacturer specification for i3; do not import smaller i6 dimensions.[1]

Ketone sensing0

Glucose only.[1]

Access & cost50

Commercialized in China and regional European branding; local supply not fully verified.[5]

Editor’s take

Scores are editorial judgments about the evidence and practical features, not measured comparative performance or a probability of success.

The full picture

iCan i3 supplies readings every three minutes, with a two-hour warm-up and configurable glucose alerts. The current Sinocare page lists age 2+; use the local brand’s manual because labels and rollout can differ.12

The pediatric paper analysed 75 participants per protocol, using the poorer-performing of two abdominal sensors. Overall MARD was 8.89%; mean sensor life was 14.4 days. No device-related or skin-related adverse events were reported. This was a prospective single-arm accuracy study, not an AID outcome or head-to-head CGM trial.3

Sinocare identifies True Vie i3 as the US investigational name. Its ADA 2026 release reports 142 adults analysed, separately from registry enrollment totals and from the pediatric paper. A US study or claimed iCGM performance does not establish FDA clearance.4

The manufacturer records i3 commercialization in China in 2023 and separate i6 products from 2025. European branding includes GlucoMen iCan; national purchasing, reimbursement and exact model equivalence should be checked locally.52

References

  1. Sinocare iCan i3 specifications and regional indication. https://uk.icancgm.com/products/ican-i3/ ↩

  2. GlucoMen iCan user guide, April2025. https://menarini-diabetes.com/wp-content/uploads/2025/06/59063-User-Manual-GlucoMem-iCan-CGM-EN-mmol-Rev-04-25.pdf ↩ ↩2

  3. Wang et al. Pediatric CGM performance study. https://doi.org/10.1177/19322968261463536 ↩

  4. Sinocare ADA2026 adult and pediatric reports. https://www.sinocare.com/sannuo/web/en/newsinfo_1276.html ↩

  5. Sinocare product history and i3/i6 launch distinctions. https://www.sinocare.com/sannuo/web/zh/sugerinfo_4_756.html ↩

Sources

  1. [1]Sinocare iCan i3 specifications and regional indication · manufacturer
  2. [2]Wang et al. Pediatric CGM performance study · peer-reviewed
  3. [3]Sinocare ADA 2026 adult and pediatric reports · manufacturer
  4. [4]GlucoMen iCan user guide, April 2025 · manufacturer
  5. [5]Sinocare product history and i3/i6 launch distinctions · manufacturer